A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy

Journal of Cardiology

Volumn 60, Issue 1, 2012, Pages 12-17

  Nakamura, Takamitsu ^a   Hirano, Mitsumasa ^a   Kitta, Yoshinobu ^a   Fujioka, Daisuke ^a   Saito, Yukio ^a   Kawabata, Ken ichi ^a   Obata, Jun ei ^a   Watanabe, Yosuke ^a   Watanabe, Kazuhiro ^a   Kugiyama, Kiyotaka ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Anti dyslipidemic agents; Cholesterol lowering drugs; Endothelium; Hyperlipoproteinemia; Vasodilation

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN;

ADULT; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; ENDOTHELIUM; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPOPROTEINEMIAS; LIPOPROTEINS; MALE; MIDDLE AGED; TRIGLYCERIDES; VASODILATION;

EID: 84864026904     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.02.005     Document Type: Article

References (30)

1. McNamara J.R., Shah P.K., Nakajima K., Cupples L.A., Wilson P.W., Ordovas J.M., Schaefer E.J. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001, 154:229-236.
2. Nakamura T., Obata J.E., Hirano M., Kitta Y., Fujioka D., Saito Y., Kawabata K.I., Watanabe K., Watanabe Y., Mishina H., Kugiyama K. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis 2011, 218:163-167.
3. Nakamura T., Obata J.E., Takano H., Kawabata K., Sano K., Kobayashi T., Fujioka D., Saito Y., Yano T., Kugiyama K. High serum levels of remnant lipoproteins predict ischemic stroke in patients with metabolic syndrome and mild carotid atherosclerosis. Atherosclerosis 2009, 202:234-240.
4. Fukushima H., Sugiyama S., Honda O., Koide S., Nakamura S., Sakamoto T., Yoshimura M., Ogawa H., Fujioka D., Kugiyama K. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J Am Coll Cardiol 2004, 43:2219-2224.
5. Tenenbaum A., Fisman E.Z., Motro M., Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006, 5:20.
6. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association.
7. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
8. Pearson T.A., Laurora I., Chu H., Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000, 160:459-467.
9. Sano K., Nakamura T., Hirano M., Kitta Y., Kobayashi T., Fujioka D., Saito Y., Yano T., Watanabe K., Watanabe Y., Mishina H., Obata J.E., Kawabata K., Kugiyama K. Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein. Circ J 2010, 74:1644-1650.
10. Bays H.E., Neff D., Tomassini J.E., Tershakovec A.M. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 2008, 6:447-470.
11. Knopp R.H., Gitter H., Truitt T., Bays H., Manion C.V., Lipka L.J., LeBeaut A.P., Suresh R., Yang B., Veltri E.P. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003, 24:729-741. Ezetimibe Study Group.
12. Davidson M.H., Ballantyne C.M., Kerzner B., Melani L., Sager P.T., Lipka L., Strony J., Suresh R., Veltri E. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004, 58:746-755. Ezetimibe Study Group.
13. Denke M., Pearson T., McBride P., Gazzara R.A., Brady W.E., Tershakovec A.M. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res 2006, 3:93-102.
14. Pearson T.A., Denke M.A., McBride P.E., Battisti W.P., Brady W.E., Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005, 80:587-595.
15. Mikhailidis D.P., Lawson R.W., McCormick A.L., Sibbring G.C., Tershakovec A.M., Davies G.M., Tunceli K. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 2011, 27:1191-1210.
16. Ballantyne C.M., Abate N., Yuan Z., King T.R., Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005, 149:464-473.
17. Masuda D., Nakagawa-Toyama Y., Nakatani K., Inagaki M., Tsubakio-Yamamoto K., Sandoval J.C., Ohama T., Nishida M., Ishigami M., Yamashita S. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009, 39:689-698.
18. Bozzetto L., Annuzzi G., Corte G.D., Patti L., Cipriano P., Mangione A., Riccardi G., Rivellese A.A. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 2011, 217:142-148.
19. Tomassini J.E., Mazzone T., Goldberg R.B., Guyton J.R., Weinstock R.S., Polis A., Jensen E., Tershakovec A.M. Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diab Obes Metab 2009, 11:855-864.
20. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003, 23:168-175.
21. Kitta Y., Obata J.E., Nakamura T., Hirano M., Kodama Y., Fujioka D., Saito Y., Kawabata K., Sano K., Kobayashi T., Yano T., Nakamura K., Kugiyama K. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol 2009, 53:323-330.
22. Nakamura T., Takano H., Umetani K., Kawabata K., Obata J.E., Kitta Y., Kodama Y., Mende A., Ichigi Y., Fujioka D., Saito Y., Kugiyama K. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005, 181:321-327.
23. Uemura Y., Watarai M., Ishii H., Koyasu M., Takemoto K., Yoshikawa D., Shibata R., Matsubara T., Murohara T. Atorvastatin 10mg plus ezetimibe 10mg compared with atorvastatin 20mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol 2012, 59:50-56.
24. Kugiyama K., Doi H., Motoyama T., Soejima H., Misumi K., Kawano H., Nakagawa O., Yoshimura M., Ogawa H., Matsumura T., Sugiyama S., Nakano T., Nakajima K., Yasue H. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 1998, 97:2519-2526.
25. Kastelein J.J., Akdim F., Stroes E.S., Zwinderman A.H., Bots M.L., Stalenhoef A.F., Visseren F.L., Sijbrands E.J., Trip M.D., Stein E.A., Gaudet D., Duivenvoorden R., Veltri E.P., Marais A.D., de Groot E., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443.
26. Al Badarin F.J., Kullo I.J., Kopecky S.L., Thomas R.J. Impact of ezetimibe on atherosclerosis: is the jury still out?. Mayo Clin Proc 2009, 84:353-361.
27. Settergren M., Bohm F., Ryden L., Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 2008, 29:1753-1760.
28. Ostad M.A., Eggeling S., Tschentscher P., Schwedhelm E., Böger R., Wenzel P., Meinertz T., Munzel T., Warnholtz A. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis 2009, 205:227-232.
29. Cannon C.P., Giugliano R.P., Blazing M.A., Harrington R.A., Peterson J.L., Sisk C.M., Strony J., Musliner T.A., McCabe C.H., Veltri E., Braunwald E., Califf R.M. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008, 156:826-832. IMPROVE-IT Investigators.
30. Itakura H., Nakaya N., Kusunoki T., Shimizu N., Hirai S., Mochizuki S., Ishikawa T. Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: efficacy and incidence of cardiac and other events in elderly patients (≥65 years old). J Cardiol 2011, 57:77-88.